Filing summary
Registrant discrepancy: Although the request metadata names HYPERION DEFI, INC., the supplied Form 10-Q is for Eyenovia, Inc. (Nasdaq: EYEN). This summary covers Eyenovia’s quarter ended June 30, 2023; the financial statements are unaudited.
Business context and reporting period
Eyenovia is an ophthalmic technology company developing its Optejet drug-delivery system and related drug-device products. It reported for the three and six months ended June 30, 2023, with prior-year comparisons to the same periods in 2022. The company had no recurring revenue and had not achieved profitability.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | No recurring revenue reported | No recurring revenue reported | No recurring revenue reported | No recurring revenue reported |
| Operating expenses | $6.0 million | $7.1 million | $11.4 million | $14.3 million |
| Net loss | $6.2 million | $7.2 million | $12.0 million | $14.6 million |
| Net loss per share | $0.16 | $0.22 | $0.32 | $0.46 |
There were no meaningful revenue-based margins to report. For the six months, operating cash use was $11.7 million, versus $12.9 million a year earlier; investing cash use was $2.1 million, versus $0.4 million; and financing provided $8.4 million, versus $15.3 million. Cash and cash equivalents fell to $17.5 million at June 30 from $22.9 million at year-end 2022. Working capital was $19.2 million, down from $23.1 million.
Gross notes payable were $15.8 million, compared with $10.4 million at December 31, 2022. In May, Eyenovia drew an additional $5.0 million under its Avenue facility; the facility’s outstanding balance matures November 1, 2025, with interest-only payments extended through May 2024. Total liabilities were $18.8 million and stockholders’ equity was $10.5 million at quarter-end.
Material changes versus the prior comparable period
- Six-month net loss improved by $2.6 million, while operating expenses declined $2.9 million. Management attributed lower R&D costs primarily to completion of the VISION-2 study in 2022 and lower stock compensation; lower G&A primarily reflected reduced professional fees and promotional spending.
- Interest expense increased to $1.0 million for the first half from $0.3 million, largely due to Avenue debt and debt-discount amortization.
- Property and equipment purchases rose to $2.1 million from $0.3 million, and property and equipment, net, increased to $3.7 million from $1.3 million at year-end.
- Common shares outstanding increased to 38.2 million from 36.7 million at year-end, partly reflecting at-the-market sales. The six-month ATM program generated approximately $3.9 million in net proceeds.
Outlook, risks, and notable items
- Going concern: Management stated that substantial doubt exists about Eyenovia’s ability to continue as a going concern for at least one year from issuance of the financial statements. Continued operations depend on additional capital, licensing or business-development transactions, or other financing. Without funding, the company may have to curtail R&D or reduce other costs.
- Mydcombi: The FDA approved Mydcombi on May 5, 2023. The company reported its first commercial sale on August 3, 2023, after quarter-end, and described a targeted launch with broader launch preparations for 2024 as internal manufacturing capacity comes online.
- Pipeline and partnerships: MicroPine and MicroLine remain development programs; Eyenovia reported positive top-line VISION-2 results in 2022. Licensing arrangements with Bausch + Lomb and Arctic Vision may provide milestone, royalty, or supply-related proceeds, but amounts and timing are contingent.
- Commitments: Management identified approximately $2.7 million of current accounts payable and accrued liabilities, $0.4 million of lease commitments, and $1.0 million of potential note payments due within 12 months. It also disclosed $1.5 million of potential executive severance obligations under specified termination conditions. Non-current notes payable were $14.8 million.
- The company reported no material legal proceedings and no material changes to the risk factors in its prior annual report. Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Eyenovia, not HYPERION DEFI, INC.
- Assess cash runway and financing needs in light of $17.5 million cash, $11.7 million six-month operating cash use, and the disclosed going-concern doubt.
- Track Mydcombi commercialization, manufacturing readiness, product uptake, and costs associated with the planned broader launch.
- Review the terms, interest burden, repayment schedule, and potential dilution associated with debt, convertible notes, ATM issuance, options, and warrants.
- Monitor clinical and regulatory progress, as well as the timing and conditions of potential licensing milestones and partner-related proceeds.